• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Fraud at Investigator Sites - P. Below Consulting
Fraud at Investigator Sites - P. Below Consulting

... Initial, date and explain (if necessary) all CRF changes/corrections. CRF designees must be documented. ...
glucovision - Canadian Association of Nuclear Medicine
glucovision - Canadian Association of Nuclear Medicine

... lung neoplasms.A total of 99 patients evaluated were visually observed during PET scan for evidence of adverse events. No adverse events were observed. A single-centre prospective study was conducted in oncology patients to evaluate the safety of fludeoxyglucose F-18. Three hundred and twelve adult ...
[ICH E2F] [EXAMPLE DSUR – PHASE III INVESTIGATIONAL DRUG
[ICH E2F] [EXAMPLE DSUR – PHASE III INVESTIGATIONAL DRUG

Emerging Drug Trends 2014
Emerging Drug Trends 2014

System suitability test
System suitability test

... may differ significantly in their bioavailability, rate of metabolism, metabolites, excretion, potency and selectivity for receptors, transporters and/or enzymes, and toxicity. The use of singleenantiomer drugs can potentially lead to simpler and more selective pharmacologic profiles, improved thera ...
Assessment of Drug−Lipid Complex Formation by a High
Assessment of Drug−Lipid Complex Formation by a High

... modify the physicochemical properties of potential drug candidates, as they have to be relatively hydrophobic and small in order to be able to penetrate through BBB.5,20,23 Simply avoiding the use of amphiphilic compounds is thus not possible. The observed close connection of the physicochemical pro ...
Revised: December 2016 AN: 00745/2016 SUMMARY OF
Revised: December 2016 AN: 00745/2016 SUMMARY OF

... In 2 clinical studies with 98 cats treated with ciclosporin the following undesirable effects were observed: Very common: gastrointestinal disturbances such as vomiting and diarrhoea. These are generally mild and transient and do not require the cessation of the treatment. Common: lethargy, anorexia ...
Overview of Oral Modified-Release Opioid Products for
Overview of Oral Modified-Release Opioid Products for

... tables. First, these tables are often estimates based on single-dose parenteral studies. Second, there is considerable interpatient variability in the efficacy and safety response to opioids due to tolerance and cross tolerance, pharmacokinetic and pharmacodynamic variability, use of coanalgesics an ...
Zohydro™ Approval by Food and Drug Administration: Controversial
Zohydro™ Approval by Food and Drug Administration: Controversial

... suffer from severe pain -- the correct number is 22.6 million. This manuscript analyzes 3 important principles of drug approval and utilization based on safety, efficacy, and medical necessity. Based on the limited literature that the authors were able to review including that which was submitted to ...
use
use

... •Long history of use •The mechanism was thought to be urine acidification •Now E. coli (other pathogens also) adhesion inhibitors are known to be present but not in other juices. An unidentified, high mol wt material may be responsible •Need about 8-16 oz (240-480ml) of juice (not drink or cocktail) ...
Investigator`s brochure
Investigator`s brochure

... and trade name (if approved). List the active ingredients and confirm which pharmacological class the IP is in. Briefly discuss its expected position within this class (i.e., the advantages it is expected to have over other products in that class). Identify the anticipated prophylactic, therapeutic ...
The position of drugs used in traditional medicine within the Indian
The position of drugs used in traditional medicine within the Indian

... on trial and error in order to treat ailments confronted. The latter one is based on the codified written systems of medicine with their own theoretical and philosophical explanations. The research in the latter stream is better than the former one. The respect, preservation, maintenance and validat ...
Levonorgestrel - Therapeutic Goods Administration
Levonorgestrel - Therapeutic Goods Administration

Appendix F  Human Gene Transfer Clinical Trials
Appendix F Human Gene Transfer Clinical Trials

... Biosafety Manual – May 2016 ...
Towards early inclusion of children in tuberculosis drugs trials: a
Towards early inclusion of children in tuberculosis drugs trials: a

... guidance documents require that children be enrolled in research only if the research cannot be done in adults.41 Other guidelines propose initiating paediatric studies (phase 1 or 2), especially in children with serious and lifethreatening diseases who could benefit from the study intervention, aft ...
CUSTOM CARBON-14 RADIOLABELLING
CUSTOM CARBON-14 RADIOLABELLING

AM: 01082/2014 Revised: December 2014 SUMMARY OF
AM: 01082/2014 Revised: December 2014 SUMMARY OF

Polymorph Impact on the Bioavailability and Stability of Poorly
Polymorph Impact on the Bioavailability and Stability of Poorly

Information on new drugs at market entry: retrospective
Information on new drugs at market entry: retrospective

... that it is based on the approved indication and patient population according to the summary of product characteristics.24 26 If this population is identical to the original patient populations investigated in the clinical studies submitted to the regulatory agencies during the drug approval process ...
ALENDRONIC ACID 70MG TABLETS PL 15922/0087
ALENDRONIC ACID 70MG TABLETS PL 15922/0087

... Bioequivalence has been proposed on the basis of the maximum excretion rate (Rmax) and amount of drug excreted unchanged in the urine over the entire period of sample collection (0-72 hours) (Ae0-72) of the test to reference formulation. The proposed target was 80% to 125% for the 90% confidence int ...
Drug Repositioning Approaches for the Discovery of New ’s Disease REVIEW
Drug Repositioning Approaches for the Discovery of New ’s Disease REVIEW

... phenotypic changes in animal models or even serendipitous clinical observations made in humans [17, 18]. Starting in the 1980s, “rational” target-based drug discovery served as a dominant trend in the pharmaceutical industry [19]. In target-based drug discovery, small molecule screening of compound ...
Document
Document

... 2. Characters of drug-receptor interaction 1) Saturation: Because of finitude of number of receptor molecule for unlimited drug molicular →Emax 2) Specific binding 3) Reversible binding: ionic bond, hydrogen bond, molecular attraction covalend bond. Therefore, there is competitive binding between 2 ...
Tuesday June 7, 2016 - Braeburn Pharmaceuticals
Tuesday June 7, 2016 - Braeburn Pharmaceuticals

...  changes in governmental regulations, tax rates and similar matters;  changes in generally accepted accounting principles by standard-setting bodies; and  the degree and nature of our competition. The forward-looking statements are based on our beliefs, assumptions and expectations of our future ...
Introduction - Obafemi Awolowo University, Ile-Ife
Introduction - Obafemi Awolowo University, Ile-Ife

... The drugs involved, all three of which are injectable, are filgrastim (Neupogen), an anticancer drug sold by Amgen; and two versions of the human growth hormone somatropin, Serostim, made by Serono, and Nutropin, which is sold by Genentech. Genentech issued a warning to patients, physicians, pharmac ...
Committee on Law Enforcement/Legislation
Committee on Law Enforcement/Legislation

... container, and the promotion and marketing of such drugs and devices. Manufacturing also includes the preparation and promotion and marketing of commercially available products from bulk compounds for resale by pharmacists, practitioners, or other persons. Background: The Committee reviewed recent e ...
< 1 ... 48 49 50 51 52 53 54 55 56 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report